Form 4 for NVCR NovoCure Ltd
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-27 · accession 0001562180-24-001987 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-29 | 2024-02-27 | NVCR | Puri Michal Nath | CHRO | A - Grant | $16.30 | +71.6K | 109.2K | +190% | +$1.17M |
| D | 2024-02-29 | 2024-02-27 | NVCR | Puri Michal Nath | CHRO | A - Grant | $16.30 | +109.4K | 109.4K | New | +$1.78M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2024-02-27 | A | A | 71,574 | $16.30 | 109,167 | D | — | — | (F1) Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. |
| 2 | Derivative | Stock Options (Right to buy) | 2024-02-27 | A | A | 109,443 | $16.30 | 109,443 | D | $16.30 · 2025-02-27 to 2034-02-26 | 109,443 Ordinary Shares | (F2) Options to buy 109,443 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. |